<DOC>
	<DOCNO>NCT00307736</DOCNO>
	<brief_summary>The purpose study determine safety 5-fluorouracil , bevacizumab erlotinib administer combination external beam radiation therapy ( Phase I portion ) well begin collect information whether combination treatment effective treating ( Phase II portion ) patient locally advanced rectal cancer .</brief_summary>
	<brief_title>Bevacizumab , Erlotinib 5-Fluorouracil With External Beam Radiation Therapy Locally Advanced Rectal Cancer</brief_title>
	<detailed_description>- All participant receive follow drug : 5-fluorouracil ( 5-FU ) give continuous 24-hour infusion ; Bevacizumab give intravenously ; erlotinib give orally home . In Phase I portion , look high dose erlotinib give safely combination 5-FU , bevacizumab radiation therapy . Therefore dose erlotinib may participant . The dose increase find high dose without cause serious unmanageable side effect . - Study treatment give outpatient consist 14 day cycle total 3 cycle . Patients give three study drug radiation therapy monday ( unless monday fall holiday ) . This day 1 first treatment cycle . 5-FU give continuously day 1-14 . Bevacizumab give day 1 . Erlotinib give day 1-14 . Radiation therapy perform Days 1-5 8-12 . - The following test procedure perform weekly participant receive study treatment : physical examination , measurement vital sign , height weight ; performance status ; blood work , urine sample . - At end treatment follow test perform : physical examination measurement vital sign ; performance status ; blood work ; CT scan chest , abdomen pelvis . Patients also evaluate surgery time . Patients follow every three month first three year surgery , every 6 month next two year .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically confirm primary adenocarcinoma rectum begin within 15cm anal verge determine sigmoidoscopy colonoscopy Clinical T3 T4 tumor determine endoscopic ultrasound and/or rectal MRI ECOG performance status 02 18 year age old Creatinine &lt; 2.0 Adequate hepatic function Adequate hematopoietic function Use effective mean contraception subject childbearing potential Evidence metastatic disease determine chest/abdominal/pelvic CT physical exam Prior chemotherapy radiation therapy treatment colorectal cancer Prior treatment 5FU Prior treatment tyrosine kinase inhibitor , EGFR inhibitor , VEGF inhibitor Patients must receive investigational agent Prior malignancy within last 5 year except completely excised skin cancer , situ cervical cancer Warfarin anticoagulation Coexistent malignant disease Current recent participation clinical trial ( within 4 week first day treatment ) Pregnancy Blood pressure &gt; 150/100 mmHg Unstable angina NYHA Grade II great congestive heart failure History myocardial infarction within 6 month History stroke within 6 month Clinically significant peripheral vascular disease Evidence bleed diathesis coagulopathy Presence central nervous system brain metastasis Major surgical procedure , open biopsy , significant trauma injury within 28 day prior day 0 , anticipation need major surgical procedure course study Minor surgical procedure , fine needle aspiration core biopsy within 7 day prior day 0 Pregnant lactate Urine protein : creatinine ratio &gt; equal one screen History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior day 0 ] Serious , nonhealing wound , ulcer , bone fracture</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Fluorouracil</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>erlotinib</keyword>
	<keyword>external beam radiation therapy</keyword>
	<keyword>EBRT</keyword>
</DOC>